Warum steigt der Aktienkurs von ELI LILLY AND CO?
Bullen sagen
Clinical efficacy
Late-stage trial data and responder analyses indicate retatrutide delivers substantial weight loss alongside meaningful blood sugar improvement, supporting a strong efficacy case that could drive adoption in type 2 diabetes.
Tolerability and dosing
Lower-dose retatrutide regimens showed a generally clean tolerability profile with simple titration and mostly mild gastrointestinal effects, suggesting broader suitability across a wider patient population.
Pipeline diversification
Recent regulatory progress and acquisitions that add neurology and immunology assets bolster analyst expectations for durable revenue growth and diversification beyond the core incretin franchise.
Safety limitations at higher doses
Gastrointestinal adverse events increased with higher doses and caused some treatment discontinuations, which could limit use of higher-dose regimens and cap market penetration for those dosing levels.
Comparative evidence uncertainty
Indirect cross-trial comparisons against competitors are affected by differences in trial populations and designs, preventing definitive superiority claims without head-to-head studies.
Clinical validation risk for immunology asset
Early data showing antibody reductions for the acquired immunology asset are encouraging on biomarkers but do not yet demonstrate durable clinical benefit, leaving an important validation risk for future outcomes.
